Assertio to Acquire Spectrum Pharma for $1.04B

Ticker: ASRT · Form: 8-K · Filed: 2024-03-27T00:00:00.000Z

Sentiment: bullish

Topics: acquisition, oncology, merger

Related Tickers: SPPI

TL;DR

Assertio buys Spectrum Pharma for $1.04B cash to boost oncology biz.

AI Summary

Assertio Holdings, Inc. announced on March 26, 2024, that it has entered into a definitive agreement to acquire all of the outstanding shares of Spectrum Pharmaceuticals, Inc. for $1.04 billion in cash. The transaction is expected to close in the second half of 2024, subject to customary closing conditions and regulatory approvals.

Why It Matters

This acquisition significantly expands Assertio's oncology portfolio and commercial capabilities, positioning it for substantial growth in a key therapeutic area.

Risk Assessment

Risk Level: medium — The acquisition is subject to regulatory approvals and closing conditions, which introduces uncertainty regarding the completion and timing of the transaction.

Key Numbers

Key Players & Entities

FAQ

What is the primary strategic rationale behind Assertio's acquisition of Spectrum Pharmaceuticals?

The acquisition is expected to significantly expand Assertio's oncology portfolio and commercial capabilities.

What is the total value of the transaction?

The definitive agreement is for the acquisition of all outstanding shares of Spectrum Pharmaceuticals for $1.04 billion in cash.

When is the transaction expected to be completed?

The transaction is expected to close in the second half of 2024.

Are there any specific conditions that need to be met for the acquisition to close?

Yes, the transaction is subject to customary closing conditions and regulatory approvals.

What is the ticker symbol for Assertio Holdings, Inc.?

The filing does not explicitly state the ticker symbol for Assertio Holdings, Inc., but it is registered with the SEC under file number 001-39294.

Filing Stats: 419 words · 2 min read · ~1 pages · Grade level 12 · Accepted 2024-03-27 07:40:40

Key Financial Figures

Filing Documents

01 Other Events

Item 8.01 Other Events On March 26, 2024, Assertio Holdings, Inc. (the "Company") received a letter from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") notifying the Company that the Company has regained compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market, and the matter is now closed.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ASSERTIO HOLDINGS, INC. Date: March 27, 2024 By: /s/ Sam Schlessinger Sam Schlessinger Senior Vice President, General Counsel

View on Read The Filing